Automate Your Wheel Strategy on VTRS
With Tiblio's Option Bot, you can configure your own wheel strategy including VTRS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VTRS
- Rev/Share 12.0338
- Book/Share 13.2741
- PB 0.7458
- Debt/Equity 0.9295
- CurrentRatio 5.8158
- ROIC -0.0627
- MktCap 11542134057.0
- FreeCF/Share 1.585
- PFCF 6.2081
- PE -3.3482
- Debt/Assets 0.3768
- DivYield 0.0485
- ROE -0.1992
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VTRS | Goldman | -- | Neutral | -- | $10 | June 6, 2025 |
News
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
Published: April 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options
Read More
Class Action Filed Against Viatris Inc. (VTRS) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: April 09, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 9, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=141921&wire=1 or contact Joseph E. Levi, Esq.
Read More
Viatris to Pay $335 Million for Settlement of Opioid-Related Claims
Published: April 08, 2025 by: Zacks Investment Research
Sentiment: Positive
VTRS has reached an agreement of $335 million to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Viatris Inc. of Class Action Lawsuit and Upcoming Deadlines - VTRS
Published: April 08, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. ("Viatris" or the "Company") (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Read More
Viatris Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VTRS
Published: April 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=141554&wire=1 or contact Joseph E. Levi, Esq.
Read More
Viatris Inc. Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against VTRS
Published: April 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025. Viatris is a global healthcare company that supplies medicines to patients across more than 165 countries and territories via its 26 manufacturing and packaging sites worldwide.
Read More
Viatris Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights - VTRS
Published: April 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=141527&wire=1 or contact Joseph E. Levi, Esq.
Read More
Viatris Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information – VTRS
Published: April 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=141512&wire=1 or contact Joseph E. Levi, Esq.
Read More
VIATRIS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Viatris Inc. - VTRS
Published: April 07, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 3, 2025 to file lead plaintiff applications in a securities class action lawsuit against Viatris Inc. (“Viatris” or “the Company”) (NasdaqGS: VTRS), if they purchased the Company's securities between August 8, 2024 and February 26, 2025, inclusive (the “Class Period”). This action is pending in the Uni.
Read More
Class Action Filed Against Viatris Inc. (VTRS) Seeking Recovery for Investors - Contact Levi & Korsinsky
Published: April 07, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=141496&wire=1 or contact Joseph E. Levi, Esq.
Read More
VTRS INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Viatris Inc. Investors with Substantial Losses Have Opportunity to Lead the Viatris Class Action Lawsuit
Published: April 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025, inclusive (the “Class Period”), have until June 3, 2025 to seek appointment as lead plaintiff of the Viatris class action lawsuit. Captioned Quinn v. Viatris Inc., No. 25-cv-00466 (W.D. Pa.), the Viatris class action lawsuit charges Viatris and certain of Viatris' top executives with violations of the Securities Exchange Act of 1934.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
Published: April 04, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / April 4, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Shareholders that Lost Money on Viatris Inc. (VTRS) Should Contact Levi & Korsinsky About Securities Fraud Investigation - VTRS
Published: April 03, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
Published: April 03, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , April 3, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public. So What: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
VTRS Investors Have Opportunity to Join Viatris Inc. Fraud Investigation with the Schall Law Firm
Published: April 03, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , April 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or "the Company") (NASDAQ: VTRS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Read More
ATTENTION Viatris Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
Levi & Korsinsky Announces an Investigation on Behalf of Viatris Inc. (VTRS) Shareholders Who May Have Been Affected by Fraud
Published: April 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
Viatris Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - VTRS
Published: April 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
An Investigation Has Commenced on Behalf of Viatris Inc. Shareholders. Contact Levi & Korsinsky to Discuss your VTRS Losses
Published: March 31, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
Viatris Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - VTRS
Published: March 31, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
Published: March 31, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
Published: March 28, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Viatris To Contact Him Directly To Discuss Their Options If you suffered significant losses in Viatris stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , March 28, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS).
Read More
Viatris Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VTRS
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
Viatris Inc. Announcement: If You Have Suffered Losses in Viatris Inc. (NASDAQ: VTRS), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Viatris Inc. (VTRS)
Published: March 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility – Hagens Berman
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- On February 27, 2025, investors saw the price of their shares of Viatris Inc. (NASDAQ: VTRS) tumble over 15% after the company disclosed an anticipated adverse 2025 monetary impact from the U.S. FDA's recent December 2024 determination concerning the company's oral dose manufacturing facility in Indore, India. Hagens Berman is investigating possible misconduct concerning the timing of Viatris' disclosures and urges investors who purchased Viatris shares and suffered substantial losses to submit your losses now.
Read More
Viatris Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Viatris Inc. (VTRS)
Published: March 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc. ("Viatris Inc.") (NASDAQ:VTRS) concerning possible violations of federal securities laws. Viatris issued a press release on February 27, 2025, reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics.
Read More
VTRS Investor News: Rosen Law Firm Encourages Viatris Inc. Investors to Inquire About Securities Class Action Investigation - VTRS
Published: March 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 24, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) resulting from allegations that Viatris may have issued materially misleading business information to the investing public. So What: If you purchased Viatris securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
About Viatris Inc. (VTRS)
- IPO Date 1980-03-17
- Website https://www.viatris.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Scott Andrew Smith
- Employees 32000